Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Mai 2012 16:01 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports First Quarter 2012 Financial Results

ANN ARBOR, Mich., May 10, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe...
09. Mai 2012 17:12 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T

ANN ARBOR, Mich., May 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
07. Mai 2012 16:30 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in Dilated Cardiomyopathy Patients at SCAI Scientific Sessions

ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
07. Mai 2012 16:00 ET | Quelle: Aastrom Biosciences, Inc.

Webcast Alert: Aastrom to Host First Quarter 2012 Investor Call on May 10, 2012

ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
30. April 2012 16:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom to Hold Annual Meeting of Shareholders on May 3, 2012

ANN ARBOR, Mich., April 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
05. April 2012 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Final Results from RESTORE-CLI Phase 2b Clinical Trial for Ixmyelocel-T in Treatment of Critical Limb Ischemia Published in the Peer-Reviewed Journal Molecular Therapy

ANN ARBOR, Mich., April 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
28. März 2012 16:30 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom to Present at the Needham & Company 11th Annual Healthcare Conference

ANN ARBOR, Mich., March 28, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
26. März 2012 09:15 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present New Findings on Atheroprotective Effects of Ixmyelocel-T at Keystone Symposia on Atherosclerosis

ANN ARBOR, Mich., March 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
14. März 2012 09:21 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Appoints Dr. LaVonne Lang as Head of Regulatory Affairs

ANN ARBOR, Mich., March 14, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
12. März 2012 16:11 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Fourth Quarter and Year-End 2011 Financial Results

ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...

Vorherige Seite

Nächste Seite